Research programme: phosphodiesterase IV inhibitors - BTG

Drug Profile

Research programme: phosphodiesterase IV inhibitors - BTG

Alternative Names: PDE4 inhibitors research programme - BTG; Phosphodiesterase IV inhibitors research programme - BTG; Research programme: PDE4 inhibitors - BTG

Latest Information Update: 20 Jul 2011

Price : $50

At a glance

  • Originator BTG
  • Class
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Allergic contact dermatitis; Hypersensitivity; Inflammation; Multiple sclerosis; Osteoporosis; Rheumatoid arthritis; Septic shock

Most Recent Events

  • 20 Jul 2011 Discontinued - Preclinical for Septic shock in USA (PO)
  • 20 Jul 2011 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO)
  • 20 Jul 2011 Discontinued - Preclinical for Osteoporosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top